KemPharm Inc (NASDAQ:KMPH) CEO Travis C. Mickle purchased 5,000 shares of the firm’s stock in a transaction on Friday, October 12th. The stock was bought at an average cost of $2.55 per share, with a total value of $12,750.00. Following the completion of the purchase, the chief executive officer now owns 1,679,978 shares of the company’s stock, valued at approximately $4,283,943.90. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of NASDAQ:KMPH traded down $0.03 during midday trading on Friday, hitting $2.55. 332,500 shares of the company’s stock were exchanged, compared to its average volume of 170,978. The company has a debt-to-equity ratio of -1.05, a current ratio of 1.76 and a quick ratio of 1.76. The company has a market cap of $77.00 million, a PE ratio of -0.86 and a beta of -0.31. KemPharm Inc has a 12 month low of $2.46 and a 12 month high of $8.40.
KemPharm (NASDAQ:KMPH) last posted its earnings results on Friday, August 10th. The specialty pharmaceutical company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.31. On average, equities research analysts expect that KemPharm Inc will post -2.95 earnings per share for the current fiscal year.
Several equities research analysts have weighed in on KMPH shares. Cowen downgraded shares of KemPharm from an “outperform” rating to a “hold” rating in a research note on Monday, July 9th. ValuEngine downgraded shares of KemPharm from a “buy” rating to a “hold” rating in a research note on Tuesday, July 10th. Zacks Investment Research raised shares of KemPharm from a “sell” rating to a “hold” rating in a research note on Thursday, July 12th. Oppenheimer set a $13.00 price target on shares of KemPharm and gave the company a “buy” rating in a research note on Thursday, August 9th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $11.00 price target on shares of KemPharm in a research note on Tuesday, August 14th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $10.50.
Several large investors have recently bought and sold shares of the company. C WorldWide Group Holding A S increased its position in shares of KemPharm by 3.2% during the second quarter. C WorldWide Group Holding A S now owns 399,999 shares of the specialty pharmaceutical company’s stock worth $2,600,000 after acquiring an additional 12,319 shares in the last quarter. Millennium Management LLC bought a new stake in shares of KemPharm during the first quarter worth about $122,000. Royal Bank of Canada increased its position in shares of KemPharm by 1,847.1% during the first quarter. Royal Bank of Canada now owns 24,125 shares of the specialty pharmaceutical company’s stock worth $191,000 after acquiring an additional 22,886 shares in the last quarter. Spark Investment Management LLC bought a new stake in shares of KemPharm during the second quarter worth about $176,000. Finally, Renaissance Technologies LLC increased its position in shares of KemPharm by 101.1% during the second quarter. Renaissance Technologies LLC now owns 181,800 shares of the specialty pharmaceutical company’s stock worth $1,182,000 after acquiring an additional 91,400 shares in the last quarter. 39.15% of the stock is owned by institutional investors.
KemPharm Company Profile
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder.
Featured Article: Exchange-Traded Funds (ETFs)
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.